DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Drugs Do In Nasal Passage.

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Seasonal Allergic Rhinitis; Sinusitis

Intervention: pseudoephedrine hydrochloride (Drug); cetirizine hydrochloride (Drug)

Phase: N/A

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline


The purpose of this study is to establish whether MRI scanning is a sensitive measure of the effects of existing drug treatments on nasal dimensions following challenge with intranasal allergen in subjects with hayfever. If successful this technique could be applied to increase confidence for internal decision making and ultimately may be used to assess how effective a new drug treatment is.

Clinical Details

Official title: An Investigation to Evaluate the Technique of MRI as an Assessment of the Effect of Anti-allergy Drug Treatment on Internal Nasal and Sinus Mucosal Anatomy Following Intranasal Allergen Challenge in Subjects With Seasonal Allergic Rhinitis.

Study design: N/A

Primary outcome: Cross-sectional airspace area (and thus also airspace volume) of the nasal passages

Secondary outcome: Volume of fluid identified adjacent to the airspace. Mucosal surface area. Nasal cavity volume. Nasal tissue volume derived from the nasal cavity volume less airspace and fluid volumes.


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- A medically diagnosed hay fever patient who is otherwise healthy.

- Aged 18 to 60 years.

- Body mass index less than 30 kg/m² with weight range of 50kg (females 45kg) to 100kg.

- A positive skin prick test (wheal = 3mm) for grass pollen at or within 12 months of

starting the study and/or a positive RAST (= class 2) for grass pollen at or within 12 months of starting the study.

- Baseline FEV1 = 80% predicted and a baseline FEV1/FVC = 70% predicted (using standard

predicted guidelines).

- Capable of giving informed consent which includes compliance with the requirements

and restrictions listed in the consent form.

- Available to complete all study measurements.

Exclusion Criteria:

- Pregnant or nursing females.

- Women of childbearing potential who are unwilling or unable to use an appropriate

method of contraception.

- On examination the subject is found to have any nasal abnormalities or nasal

polyposis, a history of frequent nosebleeds, or nasopharyngeal surgery.

- Recent (within 3 weeks) or ongoing chest infection which in the physician responsible

opinion renders the subject unsuitable for participation in the study.

- The subject has a history or current evidence of perennial rhinitis, sinusitis, or

any other condition potentially or directly involving the nasal cavity, sinuses or nasopharynx.

- A history of any medical condition that would not allow the use of pseudoephedrine

(e. g. hypertension, diabetes mellitus, ischaemic heart disease, raised intraocular pressure, hyperthyroidism, benign prostatic hyperplasia) or cetirizine (eg. antihistamine hypersensitivity).

- Any respiratory disease other than mild stable asthma that is controlled with

occasional use of as-needed short-acting beta-agonists and associated with normal lung function.

- The subject is likely to be unable to abstain from salbutamol use for 8 hours before

a challenge.

- The subject has a history of drug or other allergy that, in the opinion of the

physician responsible, contraindicates their participation.

- The subject has participated in another study during the previous 3 months.

- The subject is currently taking regular (or a course of) medication whether

prescribed or not, including steroids, vitamins, oral contraceptives and herbal remedies.

- The subject regularly, or on average, drinks more than 4 units of alcohol per day -

where 1 unit = ½ pint of beer (284mL), or 1 glass of wine (125mL), or 1 measure of spirit (25mL).

- The subject smokes more than 5 cigarettes per day.

- The subject has a history of porphyria.

Locations and Contacts

GSK Investigational Site, London W1G 8HU, United Kingdom
Additional Information

Starting date: March 2007
Last updated: August 30, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017